1. Satriyasa BK. Botulinum toxin (Botox®) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clin Cosmet Investig Dermatol. 2019;12:223.
2. Sundaram H, Signorini M, Liew S, de Almeida ART, Wu Y, Braz AV, et al. Global aesthetics consensus: botulinum toxin type A—evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg. 2016;137(3):518.
3. Alaqeely R, Alzahrani E, Aljaloud A, Alzahrani S. Botox® and Fillers, are they Cosmetic or Therapeutic? Saudi J Oral Dent Res. 2021 Jan 5;6(1):1–8.
4. Food and Drug Administration. BOTOX® (Botulinum Toxin Type A). 2004. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/103000s5050lbl.pdf
5. Wang JY. Clinical Uses of Botulinum Toxin in the Skin. In: Jabbari B, editor. Botulinum Toxin Treatment in Clinical Medicine . Cham: Springer International Publishing; 2018. p. 231–45. Available from: http://link.springer.com/10.1007/978-3-319-56038-0_13
6. Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014;90(3):168–75.
7. Wright G, Lax A, Mehta SB. A review of the longevity of effect of botulinum toxin in wrinkle treatments. Br Dent J. 2018 Feb;224(4):255–60.
8. Abe T, Loenneke JP. The Influence of Facial Muscle Training on The Facial Soft Tissue Profile: A Brief Review. Cosmetic 2019, 6,50. Doi: 10.3390/cosmetics6030050
9. Kaufman-Janette J, Cox SE, Dayan S, et al. Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes? Toxins. 2021 Jul 16;13(7):494.
10. Camargo CP, Xia J, Costa CS, et al. Botulinum toxin type A for facial wrinkles. Cochrane Database Syst Rev. 2021;7(7):CD011301. Published 2021 Jul 5. doi:10.1002/14651858.CD011301.pub2
11. Sethi N, Singh S, DeBoulle K, et al. A Review of Complications Due to the Use of Botulinum Toxin A for Cosmetic Indications. Aesthetic Plast Surg. 2021 Jun;45(3):1210–20.
12. Mya NK, Tat YB, Yeoh BS. et al. Botox: The deadly beauty. Forensic Med Anat Res. 2019;7(1):13–7.
13. Carruthers A, Sadick N, Brandt F, et al. Evolution of facial aesthetic treatment over five or more years: a retrospective cross-sectional analysis of continuous onabotulinumtoxinA treatment. Dermatol Surg. 2015;41(6):693–701.
14. Rivkin A, Binder WJ. Long-term effects of onabotulinumtoxinA on facial lines: a 19-year experience of identical twins. Dermatol Surg. 2015;41:S64–6